Alkermes plc (ALKS) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Alkermes plc (ALKS) right now is Orexin pipeline optionality: Alixorexton (formerly ALKS 2680) is a once-daily orexin 2 receptor agonist that delivered positive Phase 2 data in narcolepsy types 1 and 2 and entered a Phase 3 (Brilliance) program in 2026 with FDA Breakthrough Therapy designation. Revenue (TTM) is ~$1.5B. If that keeps playing out, the setup is favourable; the risk to it is clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. No one can predict where ALKS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Alkermes plc (ALKS) higher?
1. Orexin pipeline optionality
Alixorexton (formerly ALKS 2680) is a once-daily orexin 2 receptor agonist that delivered positive Phase 2 data in narcolepsy types 1 and 2 and entered a Phase 3 (Brilliance) program in 2026 with FDA Breakthrough Therapy designation. Follow-on orexin candidates (ALKS 7290, ALKS 4510) are in early human studies. This franchise is the primary long-term value driver and the main source of both upside and binary risk.
2. Cash-generative commercial base
Vivitrol, Aristada, and Lybalvi together produce over a billion dollars in annual proprietary product sales, and the portfolio is profitable on an adjusted EBITDA basis. This self-funding structure lets Alkermes finance clinical development and business development without heavy reliance on equity raises.
3. Avadel/Lumryz sleep expansion
The February 2026 acquisition of Avadel added Lumryz, a once-nightly sodium oxybate for narcolepsy, giving Alkermes an existing commercial foothold in sleep ahead of a potential alixorexton launch. Management guided Lumryz toward roughly $315 to $335 million of net sales in 2026, and the drug creates commercial and label-expansion synergies with the orexin program.
4. Portfolio life-cycle management
Lybalvi remains a growth product within the schizophrenia and bipolar franchise, while Vivitrol and Aristada are more mature. Ongoing label work and the sodium-oxybate idiopathic-hypersomnia effort aim to extend the revenue base and smooth the transition toward pipeline-driven growth.
What could weigh on ALKS?
Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. Legacy franchises face patent expiries and generic competition (notably Vivitrol and the schizophrenia injectables), which can erode the cash base that funds the pipeline. The Avadel deal added integration risk and litigation exposure tied to Lumryz's competitive position against Jazz Pharmaceuticals' oxybate products. Concentration in central-nervous-system and sleep indications leaves Alkermes exposed to specific payer, pricing, and regulatory dynamics, and as an Ireland-domiciled company it also carries tax and cross-border considerations. Any of these can drive outsized share-price swings around data and regulatory catalysts.
Where ALKS trades today
A forecast starts from where the stock actually is. These are ALKS's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for ALKS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a ALKS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the ALKS guide and whether ALKS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the ALKS outlook
The bottom line: what is driving Alkermes plc (ALKS) is Orexin pipeline optionality, with revenue (ttm) at ~$1.5B. If that keeps playing out the setup is favourable; the risk is clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. No one can predict the price, so treat any ALKS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around ALKS with Walnut
Use Alkermes plc as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Alkermes plc (ALKS)?
+
No one can reliably predict where ALKS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Alkermes plc higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive ALKS higher?
+
The main growth drivers are Orexin pipeline optionality; Cash-generative commercial base; Avadel/Lumryz sleep expansion. Whether they play out is the real question, not a guaranteed path.
What are the risks to ALKS?
+
Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. Legacy franchises face patent expiries and generic competition (notably Vivitrol and the schizophrenia injectables), which can erode the cash base that funds the pipeline. The Avadel deal added integration risk and litigation exposure tied to Lumryz's competitive position against Jazz Pharmaceuticals' oxybate products. Concentration in central-nervous-system and sleep indications leaves Alkermes exposed to specific payer, pricing, and regulatory dynamics, and as an Ireland-domiciled company it also carries tax and cross-border considerations. Any of these can drive outsized share-price swings around data and regulatory catalysts.
Will ALKS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Alkermes plc's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is ALKS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the ALKS "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.